TROV Share Price

Open 1.10 Change Price %
High 1.20 1 Day -0.15 -13.04
Low 1.00 1 Week -0.18 -15.25
Close 1.00 1 Month -1.00 -50.00
Volume 471483 1 Year -4.20 -80.77
52 Week High 6.67
52 Week Low 0.95
TROV Important Levels
Resistance 2 1.19
Resistance 1 1.11
Pivot 1.07
Support 1 0.89
Support 2 0.81
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

TrovaGene, Inc. (NASDAQ: TROV)

TROV Technical Analysis 5
As on 24th Mar 2017 TROV Share Price closed @ 1.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.71 & Strong Sell for SHORT-TERM with Stoploss of 1.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
TROV Target for March
1st Target up-side 2.17
2nd Target up-side 2.32
3rd Target up-side 2.47
1st Target down-side 1.73
2nd Target down-side 1.58
3rd Target down-side 1.43
TROV Other Details
Segment EQ
Market Capital 54819236.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.trovagene.com
TROV Address
TROV
11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States
Phone: 858-952-7570
TROV Latest News
Interactive Technical Analysis Chart TrovaGene, Inc. ( TROV NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TrovaGene, Inc.
TROV Business Profile
TrovaGene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�s urine-based test addresses market needs, such as women�s healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).